{"entity":{"id":"syntrix-pharmaceuticals","kind":"company","name":"Syntrix Pharmaceuticals","aka":["Syntrix Biosystems, Inc.","Syntrix Biosystems"],"tldr":"Syntrix Pharmaceuticals, near Seattle, develops SX-682, a tablet that blocks signals tumours use to gather immune-suppressing cells around themselves. It is in phase 2 trials, including in prostate cancer.","summary":"Syntrix Pharmaceuticals (Syntrix Biosystems, Inc.) of Auburn, Washington, develops SX-682, a small-molecule dual inhibitor of the chemokine receptors CXCR1 and CXCR2, which the company describes as inactivating immunosuppressive myeloid cells in the tumour microenvironment; it also has a pain programme. SX-682 is in phase 1 and phase 2 trials, among them NCT06228053, a Syntrix-sponsored phase 2 trial with enzalutamide in metastatic castration-resistant prostate cancer. Two 2026 National Cancer Institute SBIR awards fund a dose-expansion study of SX-682 alone and with decitabine in myelodysplastic syndromes and a phase 2 study with nivolumab and relatlimab in melanoma.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://syntrixbio.com/"},{"label":"Immuno-oncology: SX-682","url":"https://syntrixbio.com/pages/immuno-oncology/"},{"label":"NIH RePORTER: award 5R44CA291622-03","url":"https://reporter.nih.gov/project-details/11324659"},{"label":"NIH RePORTER: award 1R44CA306688-01A1","url":"https://reporter.nih.gov/project-details/11406776"}],"tags":[],"related":[],"cancers":["prostate","mds","melanoma"],"sections":["immunotherapy","targeted-therapy"],"technologies":[],"targets":[],"drugs":["sx-682"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06228053"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website (home and immuno-oncology pages) and the NIH RePORTER records read on 4 November 2026. The website says SX-682 is the only oncology therapeutic in development that blocks all parts of the CXCR1/2 axis; that is the company's claim."],"hq":"Auburn, WA","country":"US","companyType":"biotech","website":"https://syntrixbio.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":740293,"source":"https://reporter.nih.gov/project-details/11324659","note":"NCI SBIR (R44) award 5R44CA291622-03: A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients"},{"round":"Grant","year":2026,"amountUsd":406500,"source":"https://reporter.nih.gov/project-details/11406776","note":"NCI SBIR (R44) award 1R44CA306688-01A1: A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patients"}]},"route":"/companies/syntrix-pharmaceuticals/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"sx-682","kind":"drug","name":"SX-682","route":"/drugs/sx-682/"}],"trial":[{"id":"nct06228053","kind":"trial","name":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06228053/"}]}}